Nuvectis Pharma
NVCT
36 hedge funds and large institutions have $12.8M invested in Nuvectis Pharma in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 2 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
9% more funds holding
Funds holding: 33 → 36 (+3)
1.45% more ownership
Funds ownership: 7.41% → 8.86% (+1.5%)
22% less capital invested
Capital invested by funds: $16.5M → $12.8M (-$3.65M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$378K |
| 2 |
Millennium Management
New York
|
+$303K |
| 3 |
BlackRock
New York
|
+$254K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$244K |
| 5 |
Renaissance Technologies
New York
|
+$235K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWM
Moran Wealth Management
Naples,
Florida
|
-$215K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$101K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$53.5K |
| 4 |
DWA
Dorsey Wright & Associates
Pasadena,
California
|
-$18K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$3.72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
26
American International Group
New York
| $30.8K | -$143 | -16 | -0.4% |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $19K | +$11.2K | +1,259 | +116% |
|
28
Wells Fargo
San Francisco,
California
| $15.9K | +$3.9K | +437 | +30% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $10.7K | -$53.5K | -6,004 | -82% |
|
|
30
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| $10.2K | -$3.72K | -417 | -25% |
|
31
Citigroup
New York
| $9.24K | +$9.84K | +1,103 | +22,060% |
|
|
AB
32
Amalgamated Bank
New York
| $8K | -$615 | -69 | -7% |
|
33
Legal & General Group
London,
United Kingdom
| $7.01K | – | – | – |
|
|
AIP
34
Ameritas Investment Partners
Lincoln,
Nebraska
| $4.72K | – | – | – |
|
|
HCM
35
Hollencrest Capital Management
Newport Beach,
California
| $2.33K | – | – | – |
|
36
Fidelity Investments
Boston,
Massachusetts
| $17 | -$45 | -5 | -71% |
|
|
MWM
37
Moran Wealth Management
Naples,
Florida
| – | -$215K | -16,697 | Closed |
|
|
DWA
38
Dorsey Wright & Associates
Pasadena,
California
| – | -$18K | -1,396 | Closed |
|
NVCT Hedge Fund Activity: Q4 2023 in Review
36 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q4 2023, worth a combined $12.8M — down 22% from $16.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NVCT positions and 2 closed out — a net gain of 3 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $378K. The largest seller was Moran Wealth Management, exiting entirely with an estimated $215K sold.
- 36 institutional investors held Nuvectis Pharma (NVCT) as of Q4 2023, up from 33 in Q3 2023.
- Funds reported $12.8M of Nuvectis Pharma stock for Q4 2023, down 22% quarter-over-quarter.
- 5 funds opened new Nuvectis Pharma positions in Q4 2023 and 2 closed out, a net change of +3 holders.
- The largest Nuvectis Pharma buyer in Q4 2023 was Morgan Stanley, an estimated $378K added.
- The largest Nuvectis Pharma seller in Q4 2023 was Moran Wealth Management, an estimated $215K sold.
Based on aggregated 13F filings for Q4 2023.